Bellicum Pharmaceuticals, Inc.
BLCM
|
$0.0748
381.28%
6.1K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-82.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3229.12% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 726,826
http://www.bellicum.com
Sec Filling | Patents | 107 employees
(US) Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.
cancer immunotherapy
add to watch list Paper trade email alert is off
BELLUS Health Inc.
BLU
|
$14.74
0.03%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (2.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (688.59% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 1,869,211,386
http://www.bellushealth.com
Sec Filling | Patents | 40 employees
(CA) BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
chronic cough hypersensitisation treatment
add to watch list Paper trade email alert is off
Celyad SA
CYAD
|
$0.47
-12.49%
49K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-25.4% 1y) (0.0% 2d) (-11.1% 3d) (0.0% 7d) (421.67% volume)
Earnings Calendar:
Market Cap: $ 10,619,159
http://www.celyad.com
Sec Filling | Patents | 107 employees
(BE) Celyad Oncology SA engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
cancer cardiology car-t t-cell treatment ceiling
add to watch list Paper trade email alert is off
Checkmate Pharmaceuticals, Inc.
CMPI
|
$10.5
0.0%
|
Health Technology
(0.0% 1d) (0.2% 1m) (0.0% 1y) (0.2% 2d) (0.1% 3d) (0.0% 7d) (-49.8% volume)
Earnings Calendar: 2022-08-11
Market Cap:
http://www.checkmatepharma.com
Sec Filling | Patents | 22 employees
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.
cancer
add to watch list Paper trade email alert is off
ChemoCentryx, Inc.
CCXI
|
$51.99
-0.04%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.14% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,709,791,785
http://www.chemocentryx.com
Sec Filling | Patents | 82 employees
(US) ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.
cancer autoimmunity
add to watch list Paper trade email alert is off
Clovis Oncology, Inc.
CLVS
|
$0.0812
-3.94%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (26.22% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 11,770,367
http://www.clovisoncology.com
Sec Filling | Patents | 484 employees
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
acquisitions cancer prostate cancer liver treatment cancer treatments
Drugs
Rubraca (rucaparib)add to watch list Paper trade email alert is off
Akouos, Inc.
AKUS
|
$13.29
1.07%
3.46%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-11-11
Market Cap:
http://www.akouos.com
Sec Filling | Patents | 54 employees
Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA.
gene therapies t-cell genetic hearing loss ceiling
add to watch list Paper trade email alert is off
Applied Genetic Technologies Corporation
AGTC
|
$0.3936
1.23%
0.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-80.43% volume)
Earnings Calendar: 2022-11-08
Market Cap:
http://www.agtc.com
Sec Filling | Patents | 83 employees
(US) Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.
gene therapies genetic clinical trials
add to watch list Paper trade email alert is off
Applied Molecular Transport Inc.
AMTI
4
|
$0.263
-14.3%
-1.14%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-22.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (10.46% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 10,871,516
http://www.appliedmt.com
Sec Filling | Patents | 80 employees
Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.
autoimmunity metabolic treatment
add to watch list Paper trade email alert is off
Aptose Biosciences, Inc.
APTO
|
$1.3
-4.41%
-4.62%
62K
|
Health Technology
(0.0% 1d) (-6.0% 1m) (-81.2% 1y) (0.0% 2d) (0.0% 3d) (-4.1% 7d) (425.63% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 20,433,011
http://aptose.com
Sec Filling | Patents | 33 employees
(CA) Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
cancer
add to watch list Paper trade email alert is off
Aravive, Inc.
ARAV
|
$0.0401
4.74%
4M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-97.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-85.6% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 2,949,862
http://www.aravive.com
Sec Filling | Patents | 17 employees
(US) Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.
cancer t-cell ovarian cancer treatment ceiling
add to watch list Paper trade email alert is off
Athersys, Inc.
ATHX
|
$0.1018
-40.86%
95M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-90.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (46.93% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 2,290,644
http://www.athersys.com
Sec Filling | Patents | 83 employees
(US) Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
cardiovascular stem cell urea t-cell neurological ceiling
add to watch list Paper trade email alert is off
Avadim Health, Inc.
AHI
|
$1.5
0.0%
12K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-77.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-44.79% volume)
Earnings Calendar:
Market Cap: $ 12,933,648
http://www.avadimhealth.com
Sec Filling | Patents | 2 employees
Avadim Health, Inc. operates as a healthcare and wellness company, which sells products to improve immune health, neuromuscular health and skin barrier health. It operates through following segments: Retail Pharmacy/Consumer and Institutional Care. The Retail Pharmacy/Consumer segment primarily includes nationwide pharmacies and other retailers that sell direct to consumers. Institutional Care segment includes acute-care hospitals and nursing homes, as well as other long-term care facilities, including short-term rehabilitation and other facilities designed for post-hospitalization care during recovery. The company was founded by Stephen Woody in 2007 and is headquartered in Asheville, NC.
skin msa
Drugs
CVS (MAGNESIUM SULFATE, UNSPECIFIED FORM)PHUEL (MAGNESIUM SULFATE HEPTAHYDRATE)
Theraworx Patented Foam Formulation (ALLANTOIN)
Theraworx pre-moistened cloths (ALLANTOIN)
Theraworx Relief Joint Discomfort and Inflammation (FRANKINCENSE)
Theraworx Relief Muscle Cramp and Spasm Relief (MAGNESIUM SULFATE HEPTAHYDRATE)
add to watch list Paper trade email alert is off
Avalon GloboCare Corp.
AVCO
|
$0.45
-16.15%
31.11%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-14.4% 3d) (0.0% 7d) (32.38% volume)
Earnings Calendar:
Market Cap:
http://www.avalon-globocare.com
Sec Filling | Patents | 8 employees
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and provision of healthcare services. It operates through the following segments: Real Property Operating; Medical Related Consulting Services; and Development Services and Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.
immunotherapy t-cell ceiling
add to watch list Paper trade email alert is off
AVEO Pharmaceuticals, Inc.
AVEO
|
$15.0
0.0%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-03-13
Market Cap: $ 521,446,905
http://www.aveooncology.com
Sec Filling | Patents | 19 employees
(US) AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
urea
add to watch list Paper trade email alert is off
Axcella Health Inc.
AXLA
|
$4.58
-56.33%
42K
|
Health Technology
(0.0% 1d) (0.0% 1m) (993.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1982.28% volume)
Earnings Calendar: 2023-10-31
Market Cap: $ 13,500,512
http://www.axcellahealth.com
Sec Filling | Patents | 64 employees
Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.
metabolic
add to watch list Paper trade email alert is off
CymaBay Therapeutics Inc.
CBAY
|
$32.48
0.03%
8.4M
|
Health Technology
(0.0% 1d) (0.0% 1m) (224.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-56.22% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 3,726,247,895
http://www.cymabay.com
Sec Filling | Patents | 60 employees
(US) CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
education liver liver disease
add to watch list Paper trade email alert is off
Diffusion Pharmaceuticals Inc.
DFFN
4
|
$6.6
11.68%
-34.32%
350K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-6.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (308.49% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 13,465,894
http://www.diffusionpharma.com
Sec Filling | Patents | 10 employees
(US) Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
treatment
add to watch list Paper trade email alert is off
Eiger BioPharmaceuticals, Inc.
EIGR
|
$1.725
-1.45%
140K
|
Health Technology
(0.0% 1d) (-64.1% 1m) (56.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (16.88% volume)
Earnings Calendar: 2023-08-10
Market Cap: $ 2,554,375
http://www.eigerbio.com
Sec Filling | Patents | 24 employees
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
Drugs
Zokinvy (lonafarnib)add to watch list Paper trade email alert is off
Enochian Biosciences, Inc.
ENOB
4
|
$0.7
0.0%
88K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-45.7% 1y) (0.0% 2d) (8.4% 3d) (0.0% 7d) (-22.33% volume)
Earnings Calendar:
Market Cap: $ 40,798,514
http://www.enochianbio.com
Sec Filling | Patents | 10 employees
(US) Enochian Biosciences, Inc. engages in the development of genetically modified cellular and immune-therapy technologies for treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev on January 18, 2011 and is headquartered in Los Angeles, CA.
cancer immunotherapy infectious disease genetic hiv treatment
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10